Keyword: WuXi STA


Wuxi Biologics Plans Spin-off and Separate Listing of Wuxi XDC

14.07.2023 -

Chinese contract research, development, and manufacturing organization (CRDMO) Wuxi Biologics announced the planned spin-off and separate listing of its subsidiary WuXi...

Markets & Companies

Delivering Quality with Speed for European Market

20.03.2023 -

In this interview, Jinling Chen, head of WuXi STA’s drug product business, and Jamie Andrews, site head of WuXi STA’s Couvet facility, explain the company’s strategy and...


WuXi STA Opens new Parenteral Formulation Line

02.12.2022 -

WuXi STA has started up a new parenteral formulation line at its drug product site in Wuxi City, China. The company’s second line for parenteral drug product clinical and...


WuXi STA Breaks Ground on US Pharma Campus

24.08.2022 -

Chinese contract research, development and manufacturing organization WuXi STA, a subsidiary of WuXi AppTec, has broken ground on a new pharmaceutical campus in...


WuXi Expands API Competence in Asia

22.07.2022 -

WuXi AppTec and its subsidiary Wuxi STA have announced several investments in manufacturing and research in Asia, with the Changzou campus in China’s Jiangsu Province a...


WuXi STA Closes Purchase of Swiss BMS plant

11.08.2021 -

WuXi STA, CDMO subsidiary of WuXi AppTec, has completed the acquisition of a drug product manufacturing facility in Couvet, Switzerland, from US pharma Bristol Myers...


PhoenixMD and WuXi STA Ready for Cancer Trial

11.06.2019 - Canadian biotech company Phoenix Molecular Designs (PhoenixMD) and partner STA Pharmaceutical (WuXi STA), a Chinese contract development and manufacturing organization (CDMO), have...


WuXi STA and Regulus in Oligonucleotide Synthesis Pact

26.02.2018 - Two drug development specialists based in the US state of California, STA Pharmaceutical, part of the WuXi AppTec group, and Regulus Therapeutics, have agreed to collaborate on...